版本:
中国

BRIEF-Peregrine Pharmaceuticals Q3 loss per share $0.04

March 13 Peregrine Pharmaceuticals Inc

* Sees FY 2017 revenue from avid bioservices business of $60 million-$65 million

* Increasing FY Avid Bioservices business manufacturing revenue outlook to $60 - $65 million from $50 - $55 million

* Peregrine pharmaceuticals reports financial results for the third quarter of fiscal year 2017 and recent developments

* Q3 loss per share $0.04 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐